Drug lookup | Fillwise

ISOSORBIDE DINITRATE

3 general benefit · 3 not a benefit

Other products in the same Health Canada class (C01D, C01DA) — coverage varies; not interchangeable

Nitroglycerin (Transderm-Nitro): general benefit, Not a benefit, Listing status unconfirmed
Isosorbide + mononitrate (Imdur): not a benefit
Vericiguat (Verquvo): limited Use 685

ISDN · DIN 00441686 · 10mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

ISDN · DIN 00441686 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2011-08-17 · brand ISDN · ATC C01DA08 ISOSORBIDE DINITRATE · form Tablet · route Oral · ingredients ISOSORBIDE DINITRATE 10 MG · company Aa pharma inc · schedule Ethical

Check this DIN again · Health Canada product record

ISDN: Formulary list price $0.0485/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0485 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4730 · Verify on the e-Formulary ↗ (DIN 00441686)

Source record

DIN 00441686: ISDN Raw flags: chronicUseMed=Y, sec3=Y Item: 241200006; group id 366; item number 0856; lccId None; manufacturer id AAP Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0485; ministry $0.0485 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00441686 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4730

Interchangeable products

Isordil · DIN 02042622 · not recorded

Shortage status: resolved shortage (ended 2024-07-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00441686

Shortage record checked 2026-09-13T08:10:21.292534+00:00

ISDN · DIN 00441694 · 30mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

ISDN · DIN 00441694 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2011-05-10 · brand ISDN · ATC C01DA08 ISOSORBIDE DINITRATE · form Tablet · route Oral · ingredients ISOSORBIDE DINITRATE 30 MG · company Aa pharma inc · schedule Ethical

Check this DIN again · Health Canada product record

ISDN: Formulary list price $0.1135/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1135 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 00441694: ISDN Raw flags: chronicUseMed=Y, sec3=Y Item: 241200005; group id 366; item number 0857; lccId None; manufacturer id AAP Source form: Tab; strength: 30mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1135; ministry $0.1135 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00441694 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4731

Interchangeable products

Isordil · DIN 02042614 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00441694

Shortage record checked 2026-09-13T08:10:21.292534+00:00

ISDN · DIN 00670944 · 5mg · SL tablet

General benefitDormant since 2020-07-24 · checked 2026-09-02 · What does dormant mean?

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

ISDN · DIN 00670944 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Dormant since 2020-07-24 · brand ISDN · ATC C01DA08 ISOSORBIDE DINITRATE · form Tablet · route Sublingual · ingredients ISOSORBIDE DINITRATE 5 MG · company Aa pharma inc · schedule Ethical

Check this DIN again · Health Canada product record

ISDN: Formulary list price $0.0633/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0633 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6550 · Verify on the e-Formulary ↗ (DIN 00670944)

Source record

DIN 00670944: ISDN Raw flags: sec3=Y Item: 241200002; group id 366; item number 0855; lccId None; manufacturer id AAP Source form: SL Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.0633; ministry $0.0633 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00670944 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6550

Interchangeable products

Isordil · DIN 02042606 · not recorded

Shortage status: discontinued (2020-03-10, reported by AA PHARMA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00670944

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Dormant since 2020-07-24 — choose a marketed DIN from the same-category list.

Isordil · DIN 02042606 · 5mg · SL tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-08-30 — choose a marketed DIN from the same-category list.Discontinued 2001-08-30 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-08-30 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2001-08-30 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Isordil · DIN 02042606 Manufacturer: Wyeth Pharmaceuticals; listing date 1997-02-04 Health Canada: Cancelled post market since 2001-08-30 · brand ISORDIL SUBLINGUAL TABLETS 5MG · ATC C01DA08 ISOSORBIDE DINITRATE · form Tablet · route Sublingual · ingredients ISOSORBIDE DINITRATE 5 MG · company Wyeth-ayerst canada inc. · schedule Ethical

Check this DIN again · Health Canada product record

Isordil: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=26936 · Verify on the e-Formulary ↗ (DIN 02042606)

Source record

DIN 02042606: Isordil Raw flags: notABenefit=Y, sec3=Y Item: 241200002; group id 366; item number 0855; lccId None; manufacturer id WAY Source form: SL Tab; strength: 5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02042606 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=26936

Interchangeable products

ISDN · DIN 00670944 · $0.0633

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2001-08-30 — choose a marketed DIN from the same-category list.

Isordil · DIN 02042622 · 10mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-06-10 — choose a marketed DIN from the same-category list.Discontinued 2002-06-10 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-06-10 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2002-06-10 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Isordil · DIN 02042622 Manufacturer: Wyeth Pharmaceuticals; listing date 1996-10-01 Health Canada: Cancelled post market since 2002-06-10 · brand ISORDIL 10 TITRADOSE TABLETS 10MG · ATC C01DA08 ISOSORBIDE DINITRATE · form Tablet · route Oral · ingredients ISOSORBIDE DINITRATE 10 MG · company Wyeth-ayerst canada inc. · schedule Ethical

Check this DIN again · Health Canada product record

Isordil: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15699 · Verify on the e-Formulary ↗ (DIN 02042622)

Source record

DIN 02042622: Isordil Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 241200006; group id 366; item number 0856; lccId None; manufacturer id WAY Source form: Tab; strength: 10mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02042622 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15699

Interchangeable products

ISDN · DIN 00441686 · $0.0485

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2002-06-10 — choose a marketed DIN from the same-category list.

Isordil · DIN 02042614 · 30mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-08-30 — choose a marketed DIN from the same-category list.Discontinued 2001-08-30 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-08-30 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Isordil · DIN 02042614 Manufacturer: Wyeth Pharmaceuticals; listing date 1996-10-01 Health Canada: Cancelled post market since 2001-08-30 · brand ISORDIL 30 TITRADOSE TABLETS 30MG · ATC C01DA08 ISOSORBIDE DINITRATE · form Tablet · route Oral · ingredients ISOSORBIDE DINITRATE 30 MG · company Wyeth-ayerst canada inc. · schedule Ethical

Check this DIN again · Health Canada product record

Isordil: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16578 · Verify on the e-Formulary ↗ (DIN 02042614)

Source record

DIN 02042614: Isordil Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 241200005; group id 366; item number 0857; lccId None; manufacturer id WAY Source form: Tab; strength: 30mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02042614 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16578

Interchangeable products

ISDN · DIN 00441694 · $0.1135

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2001-08-30 — choose a marketed DIN from the same-category list.

Other drugs in the same formulary class (24:12 Vasodilating Drugs) and how they are covered

Matched class: 24:12 Vasodilating Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): NITROGLYCERIN 24:12 Vasodilating Drugs

NITROGLYCERIN

· 20 products · General benefit (13), Temporary benefit (2), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (4) · strengths: 0.4mg/Hr/20 Sq Cm, 0.6mg/Hr/30 Sq Cm, 0.4mg/Hr/14 Sq Cm, 0.6mg/Hr/21 Sq Cm, 0.3mg, 0.6mg, 0.4mg/Metered Dose, 0.2mg/Hr, 0.4mg/Hr, 0.6mg/Hr, 0.8mg/Hr · Patch, SL Tab, Sp-180 Dose Pk, Sp-75 Dose Pk, Spray-200 Dose Pk, Transdermal Patch

ISOSORBIDE-5-MONONITRATE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 60mg · ER Tab

VERICIGUAT

· 3 products · Limited Use, codes 685 · strengths: 2.5mg, 5mg, 10mg · Tab

DIPYRIDAMOLE & ACETYLSALICYLIC ACID

· 2 products · Listed, not a benefit (1), Limited Use, codes 349 (1) · strengths: 200mg/25mg · Cap

NIMODIPINE

· 1 products · Limited Use, codes 42, 43 · strengths: 30mg · Tab

AMBRISENTAN

· 7 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · Tab

BETAHISTINE DIHYDROCHLORIDE

· 24 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 8mg, 16mg, 24mg · Tab

BOSENTAN MONOHYDRATE

· 14 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 62.5mg, 125mg · Tab

DIPYRIDAMOLE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 25mg, 50mg, 75mg · Tab

RIOCIGUAT

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.5mg, 1.5mg, 1mg, 2.5mg, 2mg · Tab

TADALAFIL

· 73 products · Off-Formulary Interchangeable, not an ODB benefit (72), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab

VARDENAFIL HCL

· 16 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg, 5mg, 20mg · Orally Disintergrating Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:12

Full class listing Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.

What the Health Canada label says it is for

1 INDICATIONS ISDN (isosorbide dinitrate tablets) is indicated for:  Prophylaxis of ischemic heart pain associated with coronary insufficiency. ISDN may reduce the number, duration and severity of anginal attacks; exercise tolerance may be increased and nitroglycerin requirements curtailed. 1.1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (≥ 65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. See 7.1.4 Geriatrics. https://pdf.hres.ca/dpd_pm/00080707.PDF PM date: 2025-05-30 Source product: ISDN; DIN 00441686; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

ISDN · DIN 00670944 Shortage status: discontinued (2020-03-10, reported by AA PHARMA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00670944

Check this DIN again

Health Canada: dormant products

Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Isordil: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026